LIVNHealthcare · Medical DevicesThe 11 Wall Street analysts covering LivaNova Plc hold a median 12-month price target of $93 — -1.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 4 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores LivaNova Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Accruals (36): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LIVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −1.3% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Overweight | $105 |
| 2 Sept 2026 | Piper Sandler | Reiterates | Overweight | — |
| 2 Sept 2026 | Piper Sandler | Reiterates | Overweight | $87 → $90 |
| 5 Aug 2026 | Needham | Maintains | Buy | $81 → $93 |
| 5 Aug 2026 | Needham | Maintains | Buy | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $90 → $95 |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
| 1 July 2026 | Freedom Capital Markets | Initiates | Hold | — |
| 22 June 2026 | Keybanc | Maintains | Overweight | — |
| 7 May 2026 | Baird | Maintains | Outperform | — |
| 7 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | Mizuho | Maintains | Outperform | — |
| 27 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 25 Feb 2026 | Needham | Maintains | Buy | — |
| 9 Jan 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 Jan 2026 | Stifel | Maintains | Buy | — |
| 19 Dec 2025 | Keybanc | Initiates | Overweight | — |
| 17 Dec 2025 | Mizuho | Maintains | Outperform | — |
| 13 Nov 2025 | Baird | Maintains | Outperform | — |
| 13 Nov 2025 | Mizuho | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LIVN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, LivaNova Plc returned +74.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 39% of US stocks
Cheaper than 28% of US stocks
Cheaper than 20% of US stocks
Higher than 55% of US stocks
Higher than 93% of US stocks
Higher than 82% of US stocks
Higher than 71% of US stocks
Higher than 75% of US stocks
Higher than 75% of US stocks
Higher than 76% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
LivaNova Plc has a market value of $4.4B and an enterprise value of $4.2B.
Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 10.8% year on year.
Net income over the same four quarters: $188.6M, a 12.8% net margin.
Diluted earnings per share, trailing twelve months: $3.38.
Free cash flow in the twelve months to 30 June 2026: $148.3M.
Trailing P/E: 23.6×; forward P/E: 17.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
LivaNova Plc employs 3,300 people — $446K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own LivaNova Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of LivaNova PLC’s Q3 2026 earnings call. The excerpt provides no details about the company’s results or management commentary.
Why it matters — The transcript is a source for investors following LivaNova, but the excerpt alone does not describe any business developments.
LivaNova reported third-quarter 2026 revenue growth of 10% year over year, driven by double-digit gains in its Cardiopulmonary and epilepsy businesses. The company raised its full-year revenue and adjusted earnings outlook, citing commercial execution, healthy demand and manufacturing capacity expansion progress.
Why it matters — The revenue growth and higher outlook offer LIVN watchers an update on business performance and management’s expectations.
Zacks reports on LivaNova’s Q3 earnings for the quarter ended September 2026, noting that its headline figures can be compared with Wall Street estimates and year-ago actuals. The excerpt does not provide the specific results or comparisons.
Why it matters — These comparisons would help LIVN watchers assess quarterly performance against expectations and the prior year, though the excerpt gives no figures.
LivaNova reported quarterly earnings of $1.23 per share, above the Zacks Consensus Estimate of $1.03. Earnings were $1.11 per share in the year-ago quarter.
Why it matters — The reported earnings exceeded consensus, a relevant quarterly result for investors following LIVN.
LivaNova reported third-quarter 2026 revenue of $393.1 million, up 9.9% year over year on a reported basis and 10.0% on a constant-currency basis. The company raised its full-year 2026 revenue and adjusted diluted EPS guidance; reported U.S. GAAP diluted EPS was $0.11.
Why it matters — The revenue growth and raised full-year guidance provide current operating and outlook updates for LIVN watchers.
The 11 Wall Street analysts covering LivaNova Plc have a median 12-month price target of $93, with estimates ranging from $75 to $105. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering LivaNova Plc, 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LivaNova Plc 96 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, LivaNova Plc ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies -1.3% from the last close, and Ticker Nerd's factor model ranks LivaNova Plc 96 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering LivaNova Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LIVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $75 to $105 over the next 12 months.
LivaNova Plc returned +74.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
LivaNova PLC is a global medical technology company focused on designing, developing, manufacturing, and marketing therapies and devices for cardiac and neurological care. LivaNova PLC’s current business is organized around cardiopulmonary products, neuromodulation therapies, and advanced circulatory support, serving hospitals, clinicians, and healthcare systems with equipment used in cardiac surgery, temporary life support, and treatment of conditions such as drug-resistant epilepsy and difficult-to-treat depression.
The most recent item we track (Seeking Alpha, 4 Nov 2026): "LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of LivaNova PLC’s Q3 2026 earnings call. The excerpt provides no details about the company’s results or management commentary.
LivaNova PLC is a global medical technology company focused on designing, developing, manufacturing, and marketing therapies and devices for cardiac and neurological care. LivaNova PLC’s current business is organized around cardiopulmonary products, neuromodulation therapies, and advanced circulatory support, serving hospitals, clinicians, and healthcare systems with equipment used in cardiac surgery, temporary life support, and treatment of conditions such as drug-resistant epilepsy and difficult-to-treat depression. The company also provides related services and support for its medical devices, making it an important supplier in specialized hospital care and life-sustaining treatment settings. Headquartered in London, England, LivaNova PLC operates across international markets and plays a role in delivering targeted medical technologies for complex clinical needs.
CEO Mr. Vladimir A. Makatsaria · 3,300 employees · United Kingdom · https://www.livanova.com
